Europe Pharmaceutical Manufacturing Industry Outlook, 2029
The Europe Pharmaceutical Manufacturing Industry estimated to reach €282.15 billion by 2021, driven by rise in aging population.
- Bonafide Trust
- 31-12-2023
- Pages : 168
- Figures : 69
- Tables : 93
- Region : Europe
- Category : Lifescience
- Pharmaceutical
According to publisher, Europe's pharmaceutical manufacturing industry is a global leader, renowned for its robust research and development (R&D) and a commitment to high-quality medications. This report dives into the market's value, growth drivers, dynamics, segmentation, regional considerations, key trends, and the competitive landscape.
Market Insights:
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Download SampleMarket Value and Growth: The European pharmaceutical manufacturing industry boasts a substantial market value, estimated to reach €282.15 billion by 2021. While growth has slowed compared to North America and Asia Pacific, Europe remains a significant player.
Growth Drivers: Several factors contribute to Europe's market strength:
Strong Research Infrastructure:
Europe is home to leading research institutions and universities, fostering innovation and drug discovery.
Example: Collaborations between pharmaceutical companies and academic institutions like the Max Planck Society in Germany accelerate development of new treatments.
Strict Regulatory Standards:
Europe enforces stringent regulations (e.g., EMA guidelines) ensuring the safety, efficacy, and quality of manufactured drugs. This builds trust in European-made pharmaceuticals globally.
Example: The rigorous approval process for new drugs in Europe guarantees a high standard of patient safety.
Aging Population:
Similar to other regions, Europe faces an aging population, driving demand for medications for chronic diseases like Alzheimer's and cardiovascular conditions.
Example: Increased production of dementia medications to manage the growing elderly population across Europe.
Market Dynamics
The European pharmaceutical manufacturing industry is a complex ecosystem shaped by several key trends:
Focus on Specialty Drugs:
The market is witnessing a shift towards specialty drugs, which target specific diseases and often come with higher price tags.
Example: Growing production of biologics for targeted cancer therapies and autoimmune disorders.
Cost Pressures and Generics:
Rising healthcare costs are pressuring manufacturers to control drug prices. This leads to a rise in generic drug production to offer more affordable alternatives.
Example: European governments might incentivize the production of generic versions of off-patent drugs to reduce healthcare expenditures.
Focus on Sustainability:
Environmental concerns are driving efforts towards sustainable manufacturing practices. Companies are implementing eco-friendly processes and reducing waste generation.
Example: Pharmaceutical companies in Europe might invest in energy-efficient production facilities and explore ways to recycle or repurpose manufacturing byproducts.
Market Segments
The European pharmaceutical manufacturing industry can be segmented based on various criteria:
Product Type:
The industry manufactures a wide range of products, including prescription drugs, over-the-counter medications, vaccines, and biopharmaceuticals.
Therapeutic Area:
Drugs are developed to target specific therapeutic areas like oncology, cardiology, and neurology.
Regional Analysis
While Europe functions as a single market, there are variations in terms of specialization and production strength within the region:
Western Europe:
Western Europe, particularly Germany, Switzerland, and France, is a hub for research and development, housing major pharmaceutical companies and renowned research centers.
Example: Many leading Big Pharma companies have their headquarters or major R&D facilities in Western Europe.
Eastern Europe:
Eastern Europe, like Poland and Hungary, is emerging as a cost-competitive manufacturing hub, attracting companies seeking lower production costs.
Example: Pharmaceutical companies might establish manufacturing plants in Eastern Europe to benefit from lower labor costs while maintaining European quality standards.
Key Developments
The European pharmaceutical manufacturing industry is constantly evolving:
Digitalization and Automation:
The industry is embracing digitalization and automation to streamline processes, improve efficiency, and enhance data analysis capabilities.
Example: Companies are implementing AI-powered systems to optimize production lines and predict potential quality control issues.
Open Innovation:
Collaboration between pharmaceutical companies, startups, and research institutions is fostering open innovation, accelerating drug discovery and development.
Example: A pharmaceutical company might partner with a university to develop a new drug delivery system for a specific medication.
Competitive Landscape
The European pharmaceutical manufacturing industry boasts a competitive landscape with established players and emerging companies:
Big Pharma: * Multinational pharmaceutical giants like Novartis, Roche, and Sanofi dominate the market with a strong presence in R&D and a broad portfolio of drugs. * Example: Roche's development of innovative cancer treatments exemplifies the European focus on high-value specialty drugs.
Specialty Pharmaceutical Companies:
Alongside Big Pharma, smaller companies specializing in niche areas like orphan drugs (treating rare diseases) or specific drug delivery technologies are gaining traction.
Example: A company might focus on developing treatments for neglected tropical diseases prevalent in developing countries.
Generic Drug Manufacturers:
Generic drug manufacturers play a crucial role in Europe's pharmaceutical landscape, providing affordable alternatives to brand-name drugs after patent expiry.
Example: Generic manufacturers in countries like France and Germany contribute significantly to the affordability of essential medications within Europe.
Contract Manufacturing Organizations (CMOs):
CMOs are playing an increasingly important role, offering production expertise and infrastructure to pharmaceutical companies.
Example: A Big Pharma company might partner with a CMO in Eastern Europe for large-scale production of a generic drug.
Conclusion
Europe's pharmaceutical manufacturing industry remains a global leader, balancing innovation with strict quality control. While facing challenges like cost pressures and competition from other regions, Europe's focus on cutting-edge research, open collaboration, and sustainable practices positions it for continued success. The future of European pharmaceutical manufacturing lies in leveraging digital advancements, fostering collaborative innovation, and ensuring the affordability and accessibility of life-saving medications for patients worldwide.
Table of Contents
- 1 Introduction 10
- 1.1 Industry Definition and Research Scope 10
- 1.1.1 Industry Definition 10
- 1.1.2 Research Scope 11
- 1.2 Research Methodology 14
- 1.2.1 Overview of Market Research Methodology 14
- 1.2.2 Market Assumption 15
- 1.2.3 Secondary Data 15
- 1.2.4 Primary Data 15
- 1.2.5 Data Filtration and Model Design 16
- 1.2.6 Market Size/Share Estimation 17
- 1.2.7 Research Limitations 18
- 1.3 Executive Summary 19
- 2 Market Overview and Dynamics 22
- 2.1 Market Size and Forecast 22
- 2.1.1 Impact of COVID-19 on World Economy 25
- 2.1.2 Impact of COVID-19 on the Market 28
- 2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery 30
- 2.2 Major Growth Drivers 34
- 2.3 Market Restraints and Challenges 41
- 2.4 Emerging Opportunities and Market Trends 44
- 2.5 Porter’s Fiver Forces Analysis 48
- 3 Segmentation of Europe Market by Formulation 52
- 3.1 Market Overview by Formulation 52
- 3.2 Tablets 54
- 3.3 Capsules 55
- 3.4 Injectable 56
- 3.5 Sprays 57
- 3.6 Suspensions 58
- 3.7 Powders 59
- 3.8 Other Formulations 60
- 4 Segmentation of Europe Market by Route of Administration 61
- 4.1 Market Overview by Route of Administration 61
- 4.2 Oral Medicine 63
- 4.3 Topical Medicine 64
- 4.4 Parenteral Medicine 65
- 4.5 Inhalations 66
- 4.6 Other Routes of Administration 67
- 5 Segmentation of Europe Market by Consumer Group 68
- 5.1 Market Overview by Consumer Group 68
- 5.2 Children & Adolescents (17 years old and below) 70
- 5.3 Adults (18-64 years old) 71
- 5.4 Geriatric (65 years old and above) 72
- 6 Segmentation of Europe Market by Therapeutic Application 73
- 6.1 Market Overview by Therapeutic Application 73
- 6.2 Cardiovascular Diseases 75
- 6.3 Pain 76
- 6.4 Diabetes 77
- 6.5 Cancer 78
- 6.6 Respiratory Diseases 79
- 6.7 Neurological Diseases 80
- 6.8 Orthopedics 81
- 6.9 Other Applications 82
- 7 Segmentation of Europe Market by Drug Type 83
- 7.1 Market Overview by Drug Type 83
- 7.2 Branded Prescription Drugs 85
- 7.3 Generic Prescription Drugs 86
- 7.4 OTC Drugs 87
- 8 Segmentation of Europe Market by Distribution Channel 88
- 8.1 Market Overview by Distribution Channel 88
- 8.2 Retail Channels 90
- 8.3 Non-retail Channels 91
- 9 Segmentation of Europe Market by Manufacturing Facility 92
- 9.1 Market Overview by Manufacturing Facility 92
- 9.2 In-house Facility 94
- 9.3 Outsourced Facility 95
- 10 European Market 2022-2032 by Country 96
- 10.1 Overview of European Market 96
- 10.2 Germany 99
- 10.3 U.K. 101
- 10.4 France 103
- 10.5 Spain 105
- 10.6 Italy 107
- 10.7 Netherlands 109
- 10.8 Rest of European Market 111
- 11 Competitive Landscape 113
- 11.1 Overview of Key Vendors 113
- 11.2 New Product Launch, Partnership, Investment, and M&A 116
- 11.3 Company Profiles 117
- Abbott Laboratories 117
- Aenova Group 119
- Amgen Inc. 123
- AstraZeneca 126
- Catalent Inc. 129
- Eli Lilly and Company 132
- F. Hoffmann-La Roche Ltd. 134
- Gilead Sciences Inc. 136
- GlaxoSmithKline plc 138
- Johnson & Johnson 142
- Lonza Group 144
- Lupin Limited 147
- Merck & Co., Inc. 149
- Novartis AG 151
- Novo Nordisk 153
- Patheon Inc. 156
- Pfizer CentreSource 160
- Sanofi SA 164
- Takeda 166
- RELATED REPORTS 168
Table 1. Snapshot of Europe Pharmaceutical Manufacturing Industry in Balanced Perspective, 2022-2032 20
Table 2. World Pharmaceuticals Output by Region, 2022-2025, annual percentage change 24
Table 3. World Economic Outlook, 2021-2031 26
Table 4. World Economic Outlook, 2021-2023 27
Table 5. Scenarios for Economic Impact of Ukraine Crisis 31
Table 6. World Health Spending by Region, $ bn, 2013-2020 40
Table 7. Main Product Trends and Market Opportunities in Europe Pharmaceutical Manufacturing Industry 44
Table 8. Europe Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 52
Table 9. Europe Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 61
Table 10. Europe Pharmaceutical Manufacturing Industry by Consumer Group, 2022-2032, $ mn 68
Table 11. Europe Pharmaceutical Manufacturing Industry by Therapeutic Application, 2022-2032, $ mn 73
Table 12. Europe Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 83
Table 13. Europe Pharmaceutical Manufacturing Industry by Distribution Channel, 2022-2032, $ mn 88
Table 14. Europe Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2022-2032, $ mn 92
Table 15. Europe Pharmaceutical Manufacturing Industry by Country, 2022-2032, $ mn 98
Table 16. Germany Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 100
Table 17. Germany Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 100
Table 18. Germany Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 100
Table 19. U.K. Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 102
Table 20. U.K. Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 102
Table 21. U.K. Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 102
Table 22. France Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 104
Table 23. France Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 104
Table 24. France Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 104
Table 25. Spain Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 106
Table 26. Spain Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 106
Table 27. Spain Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 106
Table 28. Italy Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 108
Table 29. Italy Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 108
Table 30. Italy Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 108
Table 31. Netherlands Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 110
Table 32. Netherlands Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 110
Table 33. Netherlands Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 110
Table 34. Pharmaceutical Manufacturing Industry in Rest of Europe by Country, 2022-2032, $ mn 112
Table 35. Abbott Laboratories: Company Snapshot 117
Table 36. Abbott Laboratories: Business Segmentation 118
Table 37. Abbott Laboratories: Product Portfolio 118
Table 38. Aenova Group: Company Snapshot 119
Table 39. Aenova Group: Business Segmentation 120
Table 40. Aenova Group: Revenue by Product, 2018-2019, thousand Euro 121
Table 41. Aenova Group: Recent Developments 122
Table 42. Amgen Inc.: Company Snapshot 123
Table 43. Amgen Inc.: Approved Drugs or Therapeutic Biologicals 124
Table 44. Astrazeneca: Company Snapshot 126
Table 45. Catalent Inc.: Company Snapshot 129
Table 46. Catalent Inc.: Business Segmentation in 2018 130
Table 47. Catalent Inc.: Product Portfolio 130
Table 48. Catalent Inc.: Revenue, 2018-2020, $ million 131
Table 49. Catalent Inc.: Revenue by Region in 2018 131
Table 50. Eli Lilly and Company: Company Snapshot 132
Table 51. Eli Lilly and Company: Pharmaceutical Brands 133
Table 52. F. Hoffmann-La Roche: Company Snapshot 134
Table 53. F. Hoffmann-La Roche: Business Segmentation 134
Table 54. F. Hoffmann-La Roche: Revenue, 2017-2019, $ bn 135
Table 55. Gilead Sciences: Company Snapshot 136
Table 56. Gilead Sciences: Main Products 136
Table 57. GlaxoSmithKline: Company Snapshot 138
Table 58. GlaxoSmithKline: Business Segmentation 139
Table 59. GlaxoSmithKline: Product Portfolio 140
Table 60. GlaxoSmithKline: Revenue, 2018-2020, $ bn 141
Table 61. Johnson & Johnson: Company Snapshot 142
Table 62. Johnson & Johnson: Business Segments 142
Table 63. Lonza Group: Company Snapshot 144
Table 64. Lonza Group: Business Segmentation in 2018 144
Table 65. Lonza Group: Product Portfolio 145
Table 66. Lonza Group: Revenue by Region in 2018 145
Table 67. Lupin Limited: Company Snapshot 147
Table 68. Lupin Limited: Business Segmentation 148
Table 69. Merck & Co., Inc.: Company Snapshot 149
Table 70. Merck & Co., Inc.: Business Segmentation 149
Table 71. Merck & Co., Inc.: Revenue, 2018-2020, $ bn 150
Table 72. Novartis International AG: Company Snapshot 151
Table 73. Novartis International AG: Business Segmentation 151
Table 74. Novartis International AG: Revenue, 2017-2019, $ bn 152
Table 75. Novo Nordisk: Company Snapshot 153
Table 76. Novo Nordisk: Product Portfolio 154
Table 77. Patheon Inc.: Company Snapshot 156
Table 78. Patheon Inc.: Business Segmentation in 2018 157
Table 79. Patheon Inc.: Product Portfolio 157
Table 80. Patheon Inc.: Revenue, 2017-2019, $ billion 158
Table 81. Patheon Inc.: Revenue by Region in 2018 158
Table 82. Patheon Inc.: Recent Developments 159
Table 83. Pfizer CentreSource: Company Snapshot 160
Table 84. Pfizer CentreSource: Business Segmentation in 2018 161
Table 85. Pfizer CentreSource: Product Portfolio 161
Table 86. Pfizer CentreSource: Revenue, 2017-2019, $ billion 162
Table 87. Pfizer CentreSource: Revenue by Region in 2018 162
Table 88. Hospira, Inc. (a subsidiary of Pfizer): Company Snapshot 162
Table 89. Pfizer CentreSource: Recent Developments 163
Table 90. Sanofi: Company Snapshot 164
Table 91. Sanofi: Business Segmentation 164
Table 92. Sanofi: Revenue, 2018-2020, $ bn 165
Table 93. Takeda Pharmaceutical Co. Ltd.: Company Snapshot 166
Figure 1. Research Method Flow Chart 14
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 17
Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2022-2032 19
Figure 4. Europe Pharmaceutical Manufacturing Industry, 2022-2032, $ mn 22
Figure 5. World Healthcare Services Production, annual percentage change 24
Figure 6. Impact of COVID-19 on Business 28
Figure 7. Primary Drivers and Impact Factors of Europe Pharmaceutical Manufacturing Industry 34
Figure 8. Trends in the Approval of Cancer Therapies by FDA in the Twenty-First Century 37
Figure 9. Leading Causes of Death in the World, 2000 and 2019, million 38
Figure 10. Worldwide Geriatric Population (60 years and above) by Region, 2015 & 2030, million 39
Figure 11. World Population 65 and Over, % of Total Population, 1950-2060 39
Figure 12. Primary Restraints and Impact Factors of Europe Pharmaceutical Manufacturing Industry 41
Figure 13. Investment Opportunity Analysis 45
Figure 14. Porter’s Fiver Forces Analysis of Europe Pharmaceutical Manufacturing Industry 48
Figure 15. Breakdown of Europe Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, % of Revenue 53
Figure 16. Europe Addressable Market Cap in 2023-2032 by Formulation, Value ($ mn) and Share (%) 53
Figure 17. Europe Pharmaceutical Manufacturing Industry by Formulation: Tablets, 2022-2032, $ mn 54
Figure 18. Europe Pharmaceutical Manufacturing Industry by Formulation: Capsules, 2022-2032, $ mn 55
Figure 19. Europe Pharmaceutical Manufacturing Industry by Formulation: Injectable, 2022-2032, $ mn 56
Figure 20. Europe Pharmaceutical Manufacturing Industry by Formulation: Sprays, 2022-2032, $ mn 57
Figure 21. Europe Pharmaceutical Manufacturing Industry by Formulation: Suspensions, 2022-2032, $ mn 58
Figure 22. Europe Pharmaceutical Manufacturing Industry by Formulation: Powders, 2022-2032, $ mn 59
Figure 23. Europe Pharmaceutical Manufacturing Industry by Formulation: Other Formulations, 2022-2032, $ mn 60
Figure 24. Breakdown of Europe Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, % of Sales Revenue 62
Figure 25. Europe Addressable Market Cap in 2023-2032 by Route of Administration, Value ($ mn) and Share (%) 62
Figure 26. Europe Pharmaceutical Manufacturing Industry by Route of Administration: Oral Medicine, 2022-2032, $ mn 63
Figure 27. Europe Pharmaceutical Manufacturing Industry by Route of Administration: Topical Medicine, 2022-2032, $ mn 64
Figure 28. Europe Pharmaceutical Manufacturing Industry by Route of Administration: Parenteral Medicine, 2022-2032, $ mn 65
Figure 29. Europe Pharmaceutical Manufacturing Industry by Route of Administration: Inhalations, 2022-2032, $ mn 66
Figure 30. Europe Pharmaceutical Manufacturing Industry by Route of Administration: Other Routes of Administration, 2022-2032, $ mn 67
Figure 31. Breakdown of Europe Pharmaceutical Manufacturing Industry by Consumer Group, 2022-2032, % of Sales Revenue 69
Figure 32. Europe Addressable Market Cap in 2023-2032 by Consumer Group, Value ($ mn) and Share (%) 69
Figure 33. Europe Pharmaceutical Manufacturing Industry by Consumer Group: Children & Adolescents (17 years old and below), 2022-2032, $ mn 70
Figure 34. Europe Pharmaceutical Manufacturing Industry by Consumer Group: Adults (18-64 years old), 2022-2032, $ mn 71
Figure 35. Europe Pharmaceutical Manufacturing Industry by Consumer Group: Geriatric (65 years old and above), 2022-2032, $ mn 72
Figure 36. Breakdown of Europe Pharmaceutical Manufacturing Industry by Therapeutic Application, 2022-2032, % of Revenue 74
Figure 37. Europe Addressable Market Cap in 2023-2032 by Therapeutic Application, Value ($ mn) and Share (%) 74
Figure 38. Europe Pharmaceutical Manufacturing Industry by Therapeutic Application: Cardiovascular Diseases, 2022-2032, $ mn 75
Figure 39. Europe Pharmaceutical Manufacturing Industry by Therapeutic Application: Pain, 2022-2032, $ mn 76
Figure 40. Europe Pharmaceutical Manufacturing Industry by Therapeutic Application: Diabetes, 2022-2032, $ mn 77
Figure 41. Europe Pharmaceutical Manufacturing Industry by Therapeutic Application: Cancer, 2022-2032, $ mn 78
Figure 42. Europe Pharmaceutical Manufacturing Industry by Therapeutic Application: Respiratory Diseases, 2022-2032, $ mn 79
Figure 43. Europe Pharmaceutical Manufacturing Industry by Therapeutic Application: Neurological Diseases, 2022-2032, $ mn 80
Figure 44. Europe Pharmaceutical Manufacturing Industry by Therapeutic Application: Orthopedics, 2022-2032, $ mn 81
Figure 45. Europe Pharmaceutical Manufacturing Industry by Therapeutic Application: Other Applications, 2022-2032, $ mn 82
Figure 46. Breakdown of Europe Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, % of Revenue 84
Figure 47. Europe Addressable Market Cap in 2023-2032 by Drug Type, Value ($ mn) and Share (%) 84
Figure 48. Europe Pharmaceutical Manufacturing Industry by Drug Type: Branded Prescription Drugs, 2022-2032, $ mn 85
Figure 49. Europe Pharmaceutical Manufacturing Industry by Drug Type: Generic Prescription Drugs, 2022-2032, $ mn 86
Figure 50. Europe Pharmaceutical Manufacturing Industry by Drug Type: OTC Drugs, 2022-2032, $ mn 87
Figure 51. Breakdown of Europe Pharmaceutical Manufacturing Industry by Distribution Channel, 2022-2032, % of Revenue 88
Figure 52. Europe Addressable Market Cap in 2023-2032 by Distribution Channel, Value ($ mn) and Share (%) 89
Figure 53. Europe Pharmaceutical Manufacturing Industry by Distribution Channel: Retail Channels, 2022-2032, $ mn 90
Figure 54. Europe Pharmaceutical Manufacturing Industry by Distribution Channel: Non-retail Channels, 2022-2032, $ mn 91
Figure 55. Breakdown of Europe Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2022-2032, % of Revenue 92
Figure 56. Europe Addressable Market Cap in 2023-2032 by Manufacturing Facility, Value ($ mn) and Share (%) 93
Figure 57. Europe Pharmaceutical Manufacturing Industry by Manufacturing Facility: In-house Facility, 2022-2032, $ mn 94
Figure 58. Europe Pharmaceutical Manufacturing Industry by Manufacturing Facility: Outsourced Facility, 2022-2032, $ mn 95
Figure 59. Breakdown of European Pharmaceutical Manufacturing Industry by Country, 2022 and 2032, % of Revenue 97
Figure 60. Contribution to Europe 2023-2032 Cumulative Market by Country, Value ($ mn) and Share (%) 98
Figure 61. Pharmaceutical Manufacturing Industry in Germany, 2022-2032, $ mn 99
Figure 62. Pharmaceutical Manufacturing Industry in U.K., 2022-2032, $ mn 101
Figure 63. Pharmaceutical Manufacturing Industry in France, 2022-2032, $ mn 103
Figure 64. Pharmaceutical Manufacturing Industry in Spain, 2022-2032, $ mn 105
Figure 65. Pharmaceutical Manufacturing Industry in Italy, 2022-2032, $ mn 107
Figure 66. Pharmaceutical Manufacturing Industry in Netherlands, 2022-2032, $ mn 109
Figure 67. Pharmaceutical Manufacturing Industry in Rest of Europe, 2022-2032, $ mn 111
Figure 68. Growth Stage of Europe 3D Printing Industry over the Forecast Period 113
Figure 69. Top products of AstraZeneca based on revenue from 2016 to 2019 (in million U.S. dollars) 127
Related Reports
Allows one individual to access the purchased report Read More
Allows all employees of an organization to access the purchased report. Internal sharing only Read More
Allows all employees of an organization to access the purchased report. It also permits the use of up to 4 paragraphs or 1 page of the report externally in whitepapers, press releases, and marketing collateral Read More
Safe and Secure SSL Encrypted
Quick Contacts
Want to customize this report?
We offer 10% Free Customization at the time of purchase
Get Free Customization
Trusted Partners
Budget constraints? Get in touch with us for special pricing
Request DiscountOrder Detail
- Order Placed (05 December, 2024)
- Notify To Team (05 December, 2024)
- Report updation (06 December, 2024)
- Report Quality Check (06 December, 2024)
- Report Dispatch (07 December, 2024)
- Hard Copy
Recently Viewed Products
Europe Pharmaceutical Manufacturing Industry Outlook, 2029
We are friendly and approachable, give us a call.